

Eurobio Scientific acquires Dendritics, a company specializing in antibody development and manufacture

This strategic acquisition strengthens the Group's offer
for the life sciences market

Paris, July 16, 2018 – 5.45 pm

Eurobio Scientific (FR0013240934, ALERS, eligible PEA-PME), leading French group in the fields of specialty *in vitro* medical diagnostics and life sciences, announces that it acquired Dendritics, a French company based in Lyon, specializing in antibody development and production. This acquisition was paid in cash, with no significant impact on the group's cash position.

A company recognized in the field of monoclonal antibodies

With a proprietary technology, Dendritics developed a wide range of antibodies, mainly targeting immune system cells. These antibodies are unique tools, critical for researchers working in the healthcare industry, particularly for the discovery of targets with high diagnostic, prognostic and therapeutic potential. In 2017, the company achieved a turnover of approximately 350 K€.

Assets for business development in North America and internationally

This acquisition enhances the Group's proprietary products catalog and complements its custom manufacturing offering with high quality human and murine antibodies. It enables Eurobio Scientific to offer researchers and clinicians innovative tools and to reposition its offer as closely as possible to public and private life sciences players.

Building up on current Dendritics' sales in the United States, Eurobio Scientific will also be able to develop its distribution network in this geographical area.

"This merger allows Eurobio Scientific to strengthen its production activities by offering custom antibody manufacturing services as well as an extensive portfolio of proprietary monoclonal antibodies. By using the innovative technology of Dendritics, we will also be able to develop new proprietary products, particularly in the field of diagnostics", says Jean-Michel Carle, Chairman of Eurobio Scientific's Management Board.

"For Dendritics, this merger is a major development opportunity drawing on the experience and commercial network of Eurobio Scientific. Our antibody offering and our innovative technology will thus be more accessible to researchers and clinicians, in France and abroad, thanks in particular to GenBio, the Group's US subsidiary", concludes Jean-Jacques Pin, President of Dendritics.

Upcoming financial meetings

First half 2018 Turnover: July 23, 2018

First Half 2018 Results: October 16, 2018

About Dendritics

Dendritics SAS was founded in 2005 by members of the LIR Research Institute in Dardilly (69). The company has developed a unique technology in the field of natural monoclonal antibodies: HuBBB. This technology makes it possible to activate nearly 40% of B lymphocytes and thus cover the entire adaptive immune system. HuBBB can immortalize circulating blood B cells, which are sources of human monoclonal antibodies. Dendritics has thus implemented a wide range of proprietary human and murine antibodies, in particular dedicated to the immune system, which represents a unique catalog for scientists, in their work of discovering targets with high diagnostic, prognostic and therapeutic potential.

Dendritics achieved turnover of about 350 000€ in 2017 and employs 6 people.

For more information, please visit : <http://www.dendritics.net/>

About Eurobio Scientific

Eurobio Scientific (ex Dioxonhit) is a key player in the field of specialty *in vitro* diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 120 employees and two production units based in the Paris region and in the United States.

For more information, please visit: www.eurobio-scientific.fr

The company is publicly listed on the Euronext Growth market in Paris

Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices.

Symbol : ALERS - ISIN Code: FR0013240934 - Reuters : ALERS.PA - Bloomberg : ALERS:FP

Contacts

Eurobio Scientific Group

Denis Fortier, General Manager

Hervé Duchesne de Lamotte, General Manager

Tel. +33(0) 1 69 79 64 80

Calyptus

Sophie Levesque / Mathieu Calleux

Investor Relations

Tel. +33(1) 53 65 68 68

eurobio-scientific@calyptus.net